1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Point of Care Nano-Technology, Inc.

Point of Care Nano-Technology, Inc.

PCNT
Point of Care Nano-Technology, Inc.US flagOther OTC
0.01
USD
-0.09
- -
727,906.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-1.6
-0.43
-0.35
-0.51
-200.09
-0.01
-0.87
-0.1
-0.08
Free Cash Flow per Basic Share
-1.5
-0.1
-0.04
-0.44
-0.68
- -
- -
-0.03
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.18
-2.61
-2.96
-3.42
-202.21
-127.8
-153.59
-161.06
-227.95
Tangible Book Value per Share
-0.09
-0.44
-0.75
-0.47
-0.53
-0.02
-0.1
-0.18
-0.27
Basic Weighted Avg Shares
- -
- -
- -
- -
1
1
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
- -
- -
- -
-119
- -
-1
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Oct'24
Jan'24
Apr'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Oct'24
Jan'24
Apr'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-98.15%
-140.66%
Free Cash Flow
- -
- -
-809.82%
Net Income, GAAP
- -
14,313.16%
-88.67%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.04
-0.01
-0.01
- -
-0.87
2023
-0.03
-0.01
-0.01
- -
-0.1
2024
-0.01
-0.02
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Raouf Guirguis
Sector
Healthcare
Industry
Biotechnology
Address
109 Ambersweet Way Davenport FL United States of America 33897
IPO Date
Feb 7, 2012
CIK
0001504239
Website
pointofcarenanotechnology.com
Similar Companies
Silence Therapeutics plc (SLN.L)
Arcus Biosciences, Inc. (RCUS)
Lyka Labs Limited (LYKALABS.NS)
U-Neuron Biomedical Inc (6973.TWO)
Biora Therapeutics, Inc. (BIORQ)
Acer Therapeutics Inc. (ACER)
Business
Point of Care Nano-Technology, Inc. (PCNT) develops and commercializes nanotechnology-based point-of-care diagnostic testing solutions, primarily focused on rapid saliva drug testing products for toxicology screening; the company offers EZ Saliva-II, a comprehensive device providing 90-second saliva collection, on-site screening for multiple substances including THC, amphetamines, cocaine, opiates, and benzodiazepines, split-sample technology for lab confirmation, and customizable drug panels; EZ Saliva-I serves as a specialized toxicology screen; Meka software platform enables digital chain-of-custody tracking, lab management, data storage, and real-time monitoring. PCNT targets law enforcement for roadside DUI, forensic, and post-accident testing; workplace clients in construction, manufacturing, and other safety-sensitive industries; and testing laboratories seeking efficient, legally defensible results. Incorporated in 2010 and headquartered at 109 Ambersweet Way, Davenport, Florida, the company operates primarily in the United States. In March 2024, PCNT changed its name from Unique Growing Solutions, Inc. to reflect its pivot to diagnostic technologies. On May 20, 2024, PCNT completed an asset purchase from Point of Care Nano-Technology, LLC for EZ Saliva test kit development and commercialization rights, issuing 66 million restricted common shares and appointing Dr. Raouf Guirguis as Chief Scientific Officer and director, alongside Nathan Keele to the board for marketing leadership; earlier, in April 2022, it secured an exclusive licensing agreement with Cedoga Consulting, LLC for animal nutrition intellectual property distribution in the USA, Canada, and Mexico, and a sales partnership with Lucy Pet Products Inc. for related pet supplements, though recent emphasis shifts to core diagnostics.